Table 1.
Baseline clinical characteristics
| Variable, n (%) | Placebo (n=11) | Drug (n=11) | p Value* |
|---|---|---|---|
| Age, years | 64±12.5 | 64.5±11.2 | 0.97 |
| Male gender | 9 (82) | 7 (64), | 0.34 |
| BMI, kg/m2 | 31±6.5 | 30.4±5.1 | 0.95 |
| Diagnosis | UA=6 (55), NSTEMI=5 (45) | UA=3 (27), NSTEMI=8 (73) | 0.19 |
| History of MI | 2 (18.2) | 1 (9.1) | 0.53 |
| Prior PCI | 2 (18.2) | 3 (27.3) | 0.61 |
| Family history of CAD | 9 (81.8) | 5 (45.5) | 0.19 |
| Current smoking | 3 (27.3) | 1 (9.1) | 0.44 |
| Hyperlipidaemia | 10 (91) | 6 (54.6) | 0.058 |
| Diabetes mellitus | 2 (18.2) | 3 (27.3) | 0.61 |
| Hypertension | 9 (81.8) | 8 (72.7) | 0.61 |
| Total cholesterol, mg/dL | 183±48.5 | 177.8±41.2 | 0.79 |
| TGs, mg/dL | 105 (88, 164) | 104 (61, 195) | 0.65 |
| LDL cholesterol, mg/dL | 111±46 | 102±43 | 0.63 |
| HDL cholesterol, mg/dL | 45.5±9.4 | 44.7±13 | 0.87 |
| Creatinine (mg/dL) | 1.0 (0.9, 1.1) | 1.1 (0.8, 1.2) | 0.59 |
| Baseline medications | |||
| Aspirin | 7 (64) | 5 (45) | 0.39 |
| Clopidogrel | 1 (9) | 3 (27) | 0.27 |
| β-Blockers | 3 (27) | 6 (55) | 0.19 |
| ACE inhibitors | 4 (36) | 3 (27) | 0.65 |
| Statins | 4 (36) | 5 (45) | 0.67 |
| CCBs | 2 (18) | 0 (0) | 0.14 |
| Warfarin | 0 (0) | 1 (9) | 0.31 |
| Digoxin | 0 (0) | 1 (9) | 0.31 |
| Diuretics | 2 (18) | 2 (18) | 1.00 |
| Oral hypoglycaemics | 2 (18) | 3 (27) | 0.61 |
*p Values for pretreatment comparisons are provided for descriptive purposes. Data are expressed as mean±SD, median (IQR) or number (percentage).
ACE, ACE inhibitors; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; TG, triglycerides; UA, unstable angina.